

# Christophe HÃ©zode

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5632123/publications.pdf>

Version: 2024-02-01

46  
papers

4,949  
citations

172207

29  
h-index

243296

44  
g-index

46  
all docs

46  
docs citations

46  
times ranked

5229  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy. <i>Liver International</i> , 2020, 40, 74-82.	1.9	14
2	Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study. <i>Liver International</i> , 2020, 40, 1042-1051.	1.9	10
3	Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 518-526.	2.4	63
4	Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r. <i>Hepatology</i> , 2019, 69, 513-523.	3.6	79
5	Performance Assessment of a Fully Automated Deep Sequencing Platform for HCV Resistance Testing. <i>Antiviral Therapy</i> , 2019, 24, 417-423.	0.6	12
6	Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. <i>BMC Infectious Diseases</i> , 2019, 19, 300.	1.3	5
7	Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. <i>Lancet, The</i> , 2019, 393, 1453-1464.	6.3	449
8	Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy. <i>International Journal of Women's Health</i> , 2019, Volume 11, 617-628.	1.1	2
9	Treatment of hepatitis C: Results in real life. <i>Liver International</i> , 2018, 38, 21-27.	1.9	57
10	Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 1013-1018.	2.9	43
11	Resistance analysis in patients with genotype 1b HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. <i>Journal of Hepatology</i> , 2018, 68, 895-903.	1.8	82
12	Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease. <i>Liver International</i> , 2017, 37, 1304-1313.	1.9	5
13	Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. <i>Liver International</i> , 2017, 37, 1314-1324.	1.9	68
14	Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study. <i>Hepatology</i> , 2017, 66, 736-745.	3.6	67
15	Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C. <i>Clinical Infectious Diseases</i> , 2017, 64, 1615-1618.	2.9	17
16	Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial). <i>Patient</i> , 2017, 10, 605-614.	1.1	4
17	Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis. <i>Gastroenterology</i> , 2017, 153, 49-52.e5.	0.6	125
18	Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. <i>Journal of Hepatology</i> , 2017, 66, 39-47.	1.8	100

#	ARTICLE	IF	CITATIONS
19	Randomized Controlled Trial of the NS5A Inhibitor Daclatasvir plus Pegylated Interferon and Ribavirin for HCV Genotype-4 (COMMAND-4). <i>Antiviral Therapy</i> , 2016, 21, 195-205.	0.6	18
20	Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen. <i>Hepatology</i> , 2016, 63, 1809-1816.	3.6	60
21	Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). <i>Hepatology</i> , 2016, 63, 1430-1441.	3.6	232
22	Why I do not treat patients for mild disease. <i>Liver International</i> , 2016, 36, 13-20.	1.9	5
23	Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1777-1782.	0.5	136
24	Ideal oral combinations to eradicate HCV: The role of ribavirin. <i>Journal of Hepatology</i> , 2016, 64, 215-225.	1.8	40
25	Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. <i>Journal of Hepatology</i> , 2016, 64, 292-300.	1.8	38
26	Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy. <i>Liver International</i> , 2015, 35, 1833-1844.	1.9	5
27	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 2599-2607.	13.9	945
28	Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. <i>Journal of Hepatology</i> , 2015, 62, 1047-1055.	1.8	76
29	Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. <i>Journal of Hepatology</i> , 2015, 63, 30-37.	1.8	37
30	Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. <i>Gastroenterology</i> , 2015, 149, 971-980.e1.	0.6	77
31	Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). <i>Lancet Infectious Diseases</i> , The, 2015, 15, 397-404.	4.6	267
32	Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. <i>Lancet</i> , The, 2015, 385, 2502-2509.	6.3	245
33	Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. <i>Lancet</i> , The, 2015, 385, 1087-1097.	6.3	257
34	Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection. <i>Gastroenterology</i> , 2015, 148, 355-366.e1.	0.6	49
35	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. <i>Gut</i> , 2015, 64, 948-956.	6.1	101
36	Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study. <i>PLoS ONE</i> , 2015, 10, e0145105.	1.1	4

#	ARTICLE	IF	CITATIONS
37	Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis. <i>Gastroenterology</i> , 2014, 147, 132-142.e4.	0.6	232
38	Using Pharmacokinetic and Viral Kinetic Modeling To Estimate the Antiviral Effectiveness of Telaprevir, Boceprevir, and Pegylated Interferon during Triple Therapy in Treatment-Experienced Hepatitis C Virus-Infected Cirrhotic Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5332-5341.	1.4	8
39	Reply to: From the CUPIC study: Great times are not coming (?). <i>Journal of Hepatology</i> , 2014, 60, 235-236.	1.8	0
40	Reply to: "From the CUPIC study: Great times are not coming (?)" <i>Journal of Hepatology</i> , 2014, 60, 900-901.	1.8	0
41	New nucleotide polymerase inhibitors to rapidly permit hematopoietic stem cell donation from a positive HCV-RNA donor. <i>Blood</i> , 2014, 124, 2613-2614.	0.6	10
42	Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) " NCT01514890. <i>Journal of Hepatology</i> , 2013, 59, 434-441.	1.8	407
43	Efficacy and safety of adefovir dipivoxil 20mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10mg daily. <i>Journal of Hepatology</i> , 2007, 46, 791-796.	1.8	41
44	Effect of Ribavirin in Genotype 1 Patients With Hepatitis C Responding to Pegylated Interferon Alfa-2a Plus Ribavirin. <i>Gastroenterology</i> , 2006, 131, 1040-1048.	0.6	183
45	Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2005, 42, 63-71.	3.6	269
46	Reply:. <i>Hepatology</i> , 2005, 42, 976-977.	3.6	5